Minerva Surgical

Minerva Surgical is a commercial-stage medical device company specializing in innovative, minimally invasive solutions for Abnormal Uterine Bleeding (AUB). Its product portfolio includes the Minerva EAS endometrial ablation system, the Symphion operative hysteroscopy system, the Genesys HTA ablation device, the Resectr tissue resection device, and the HERizon disposable hysteroscopy system, forming a complete intrauterine suite. The company was acquired by Axora Medical in early 2026, transitioning its employees but maintaining its operational focus on providing integrated technology, support, and training to gynecologists and healthcare facilities. Minerva's strategy centers on streamlining the diagnosis and treatment continuum for AUB with devices designed for safety, simplicity, and clinical efficacy.

Integrated suite of minimally invasive intrauterine devices utilizing multi-modal ablation (RF, thermal, fluid), continuous direct visualization, bladeless resection, and proprietary fluid management for diagnosing and treating Abnormal Uterine Bleeding.

Minerva competes in the gynecologic surgical device market against large public companies like Boston Scientific (with the NovaSure ablation system) and Hologic (with the MyoSure resection system), as well as other players like Medtronic and Stryker. Its differentiation is based on its complete suite of complementary devices, specific technology features like the triple-ablation mechanism of Minerva EAS, and a focused uterine health strategy.